🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,432 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11155549

Ester and carbonate pyrimidine compounds as JAK kinase inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11155559

Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel

CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED · Granted Tue Oct 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11147801

Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase in

Aurigene Discovery Technologies Limited · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11147885

ASH1L inhibitors and methods of treatment therewith

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Oct 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 14 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11141418

Methods and compositions for KRAS inhibitors

The Board of Regents of the University of Texas System · Granted Tue Oct 12 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135225

Cancer treatments using combinations of CDK and ERK inhibitors

Biomed Valley Discoveries, Inc. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135204

Anhydrous compositions of mTOR inhibitors and methods of use

PALVELLA THERAPEUTICS, INC. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135222

Aurora kinase inhibitors

The Regents of the University of California · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11130759

2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors

IDEAYA Biosciences, Inc. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129841

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129856

Methods of treating chronic wounds with amniotic fluid having elevated levels of tissue in

Prime Merger Sub, LLC · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129828

Pyridazinone compounds and their use as DAAO inhibitors

Takeda Pharmaceutical Company Limited · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11129805

Dual ACE C-domain/NEP inhibitors

ANGIODESIGN (UK) LIMITED · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11130778

CD73 inhibitors

ORIC PHARMACEUTICALS, INC. · Granted Tue Sep 28 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124502

Neprilysin inhibitors

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124537

Inhibitors of glucocorticoid receptor

ORIC PHARMACEUTICALS, INC. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11123340

Small-molecule UT-A-selective urea transport inhibitors

The Regents of the University of California · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11124839

Methods of treating cancer patients with farnesyltransferase inhibitors

Kura Oncology, Inc. · Granted Tue Sep 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117865

Inhibitors of bromodomain-containing protein 4 (BRD4)

The Board of Regents of the University of Texas System · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117900

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11117888

Irreversible inhibitors of pyruvate kinase M2 and the use thereof

China Medical University · Granted Tue Sep 14 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110108

Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitor

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110086

Compounds useful as inhibitors of ATR kinase and combination therapies thereof

Vertex Pharmaceuticals Incorporated · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11110090

Aminopyrimidines as ALK inhibitors

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted